Trial Profile
Phase III Study of Neoadjuvant Chemotherapy With Capecitabine and Oxaliplatin Versus Chemoradiation for Locally Advanced Rectal Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms CONVERT
- 24 Oct 2023 Final results presented at the 48th European Society for Medical Oncology Congress.
- 26 Jul 2022 Planned End Date changed from 1 Jun 2024 to 1 Mar 2024.
- 09 May 2021 Status changed from recruiting to active, no longer recruiting.